Implantable Cardioverter Defibrillator Detection During Radiofrequency Catheter Ablation of Ventricular Tachycardia

Right ventricular radiofrequency catheter ablation was performed in an ICD patient with frequent ventricular tachycardia without prior inactivation of the device. The registrations of inlracardiac ECG and marker channel were excellent during energy delivery: the surface ECG was affected. The device did not show dysfunction during and after energy delivery.     

Ventricular Pacing Induced Ventricular Tachycardia in Patients with Implantable Cardioverter Defibrillators

Appropriately timed noncompetitive ventricular pacing potentially may initiate ventricular tachycardia in patients prone to these arrhythmias. The combination of bradycardia pacing and stored electrograms in a currently available cardioverter defibrillator provides an opportunity to evaluate the occurrence of such pacing induced ventricular tachycardia. During a surveillance period of 18.7 ± 11.4 months, stored electrograms documented 302 episodes of ventricular tachycardia in 77 patients. Five patients (6.5%) demonstrated 25 episodes (1–16 per patient) of ventricular tachycardia that were immediately preceded by an appropriately paced ventricular beat (8.3% of all episodes of ventricular tachycardia). All five patients had prior myocardial infarctions and a history of monomorphic ventricular tachycardia occurring both spontaneously and in response to programmed electrical stimulation. Antitachycardia pacing terminated pacing induced ventricular tachycardia in 22 episodes; in one episode antitachycardia pacing accelerated ventricular tachycardia. In two cases shock therapy was aborted for nonsustained ventricular tachycardia. We conclude that, in selected postinfarction patients with recurrent sustained monomorphic ventricular tachycardia treated with implantable cardioverter defibrillators, appropriately timed ventricular pacing may induce ventricular tachycardia.     

Limitations of Tachycardia Confirmation and Rate Classification Algorithms in a Third-Generation Implantable Cardioverter Defibrillator

Newer ICDs provide antitachycardia (ATP) and bradycardia pacing and cardioversion and defibrillaiion shocks based on sensed interval criteria. The objectives of this investigation were to determine the algorithm related errors in tachycardia confirmation and rate classification that occurred in patients with a third-generation, noncommitted, tiered ICD therapy. Forty-three consecutive patients with the Guardian ATP 4210 ICD, which uses an X out of Y sensed interval counting algorithm for tachycardia detection, confirmation, and classification were studied. Surface ECGs, intracardiac electrograms, stored data logs, and sense histories were reviewed to diagnose errors due to these algorithms that resulted in delivery of inappropriate therapy or inhibition of appropriate therapy. Sixty-eight classification or confirmation algorithm errors from 7,610 tachycardia detections (< 1 %) were diagnosed in 23 (53%) of 43 patients. Three types of errors not related to device or sensing lead malfunction or programming mistakes were seen. In 26 episodes, the confirmation algorithm failed to detect late tachycardia reversion of nonsustained tachyarrhythmias, on the last or next to last sensed interval, and did not inhibit ATP (n = 17) or shocks (n = 9). In 28 episodes, inaccurate classification of tachycardia rate resulted in inappropriate ATP (n = 23) or shock (n = 5) therapy. In 14 episodes, the posttherapy reconfirmation algorithm produced inhibition of VVI pacing and prolonged asystole following shock therapy. These errors in tachycardia confirmation and rate classification were due to the inherent limitations of the X out of Y counting algorithm.     

The Impact of the Implantable Cardioverter Defibrillator on Quality-of-Life

The implantable Cardioverter defibrillator (ICD) is an established treatment for patients with life-threatening ventricular arrhythmias. While it clearly reduces the incidence of death from recurrent arrhythmia, little is known about the impact on patients' quality-of-life. In this prospective study, quality-of-life was assessed by questionnaire before and after ICD implantation. The "Sickness Impact Profile" (SIP), which evaluates physical, psychosocial, and other activities, as well as functions of daily life, was used. Employment and rehospitalization rates were also examined. Twenty-one of 23 consecutive patients, aged 58 ± 11 years, undergoing ICD implantation at Royal Perth Hospital were studied. During the 14 ± 8 month follow-up, 4 patients died. Functional capacity was unchanged in all but one of the survivors in whom it improved from New York Heart Association Class III to II. Four of 8 survivors employed before implant have since retired. Six patients required rehospitalization on 13 occasions, problems related to arrhythmias or the ICD. Overall SIP scores preimplant (11.2 ± 9.3; P < 0.05) were significantly worse at 6-month follow-up (21.7 ± 18.2), but returned to preimplant levels by 12-month follow-up (8.8 ± 10.8; NS). This was primarily due to transient problems in the areas of emotional behavior, alertness, and social interaction. SIP psychosocial dimension scores: preimplant: 7.2 ± 9.0; 6-month: 17.8 ± 18.1 (P < 0.05); and 12-month: 8.6 ± 10.3 (NS). Early retirement and hospitalizations due to arrhythmias may still be expected even after implantation of an ICD; however, quality-of-life appears only to temporarily decline.     

Implantable Cardioverter Defibrillator Events in Patients with Asymptomatic Nonsustained Ventricular Tachycardia:

Primary prevention trials have demonstrated that patients with coronary disease, reduced left ventricular function, and nonsustained ventricular tachycardia (NSVT) have improved survival with implantable cardioverter defibrillator (ICD) therapy, presumably secondary to effective termination of life-threatening arrhythmias. However, stored intracardiac electrograms were not always available and specific arrhythmias leading to ICD therapy were not always known. We examined the occurrence of ICD events in 51 consecutive patients who match the described patient profile to determine the frequency of appropriate and inappropriate ICD therapy. ICD detections were noted in 18 (35%) patients during a median follow-up period of 13.1 months. Appropriate therapy for sustained ventricular tachycardia (VT)/ventricular fibrillation (VF) occurred in 11 (22%) patients, with appropriate shocks in 8 (16%) patients and appropriate antitachycardia pacing (ATP) in 4 (8%) patients. The time to first appropriate therapy occurred at a mean of 17 +/- 12 months (median 18 months, range 3-36 months). Inappropriate therapy occurred in 5 (10%) patients with inappropriate shocks in 4 patients and inappropriate ATP in 2 patients. Inappropriate therapy was delivered for supraventricular arrhythmias (SVAs) in 4 patients and for T wave oversensing in 1 patient. The reason for shock therapy was unknown in 1 patient (2%) due to ICD malfunction. The mean arrhythmia rate leading to appropriate therapy for VT/VF was 232 +/- 72 beats/min (range 181-400 beats/min), and the mean rate leading to inappropriate therapy for SVT was 168 +/- 10 beats/min (range 160-180 beats/min). Patients with coronary disease and asymptomatic NSVT commonly receive appropriate defibrillator therapy. These results support the need for ICD implantation for primary prevention, with attention to careful programming of the detection rate to prevent inappropriate therapy.     

A Technique for the Prevention of Automatic Implantable Cardioverter Defibrillator Generator Migration

In order to prevent AICD generator migration in nine patients and correct chronic painful generator migration in three patients, we placed the AICD generator in an absorbable microfibrillar collagen pouch at the time of implant to facilitate fibrous capsule formation. Over a mean follow-up period of 14 +/- 2 months for the new implants, there have been no episodes of generator erosion, migration or infection. The three patients who suffered from generator migration have been symptom free for 12 +/- 2 months. We conclude that use of a microfibrillar collagen pouch at the time of AICD implant is a safe, inexpensive, and effective method for preventing generator migration.     

Early Benefit of Implantable Cardioverter Defibrillator Therapy in Patients Waiting for Cardiac Transplantation

The ICD can effectively recognize and treat ventricular arrhythmias that can lead to sudden death. Sudden death is a major problem in patients awaiting heart transplantation. We reviewed our experience with the ICD in patients with malignant ventricular arrhythmias waiting for cardiac transplantation. Nineteen patients were included. Seventeen were men, mean age was 54 ±11 years (range 17–66) and the left ventricular ejection fraction was 22%± 10% (range 9%–46%). After a mean follow–up of 6 ± 5 months (range 1–20 months), 17 patients reached heart transplantation. One patient died and the other is waiting for a transplant. Before transplantation 71 % of patients received an appropriate discharge. The mean time to the first appropriate discharge was 2 ± 2 months (range < 1–6 months), which was significantly shorter than the mean time to first discharge in the other patients (n = 182) receiving a defibrillator in our center (11 ±10 months; range 1–58 months) (P < 0.0004). In conclusion, cardiac transplantation candidates with life–threatening ventricular arrhythmias can effectively be protected against sudden arrhythmic death by ICD. These patients have a high incidence of appropriate shocks occurring very early after implantation.     

Analysis of Deaths in Patients with an Implantable Cardioverter Defibrillator

The cause of death and clinical characteristics of 26 patients that died after implantable cardioverter defibrillator placement were reviewed and compared to the 145 patients still living after a mean follow-up of 17 months. Operative mortality was 4% (7/171) and resulted from postoperative ventricular arrhythmias (four patients), heart failure (two patients), and respiratory failure (one patient). Operative mortality was significantly higher (1.7% vs 9.6%, P less than 0.05) following concomitant surgical procedures. Total late mortality was 11% (18/171). Thirteen deaths (75%) occurred in-hospital from progressive deterioration of left ventricular function (nine patients), arrhythmia (two patients), and noncardiac causes (two patients). Outpatient mortality was 3.5% (6/171) and resulted from presumed sudden cardiac death in five of six patients; two of the five had devices that were inactive, one had high defibrillation thresholds, and two had suspected bradyarrhythmic deaths. One postoperative death and one late in-hospital death were also considered sudden cardiac deaths for a total of seven patients with defibrillation system failures. By multivariant analysis, preoperative clinical characteristics associated with a worse prognosis following defibrillator implantation were identified: presentation as ventricular tachycardia (P less than 0.02), induction of sustained monomorphic ventricular tachycardia (P less than 0.05), poor left ventricular performance (P less than 0.01), poor functional status (P less than 0.001), and the use of diuretics (P less than 0.01). Frequent device discharges (P less than 0.001) and concomitant antitachycardia pacing systems (P less than 0.001) were markers for greater arrhythmia recurrence and were potent predictors of a worse prognosis and particularly sudden death.     

Holter Functions of the Implantable Cardioverter Defibrillator: What is Still Missing?

The technology of the implantable Cardioverter defibrillator (ICD) offers the opportunity to overcome the present limits of the invasive and noninvasive approaches of clinical electrophysiology. The invasive approach enables us to reproduce severe arrhythmias if they are inducible, but does not give information concerning the way they spontaneously arise. The noninvasive approach (Holter) gives this information, but it usually concerns only trivial arrhythmias with different therapeutic targets. One hopes in the future, by means of an important extension to ICD technology, which is not technically possible for the time being, to have access to pertinent information and to a better understanding of the circumstances leading to severe spontaneous arrhythmias, potentially lethal. For the moment, we only have the diagnostic certainty leading to the therapeutic intervention. It is based on an ECG and on the sequence of cardiac cycles preceding the rhythmic controlled accident. These data allow verification of but not explanation of the events. To have a chance to be understood and explained, these "events" must be replaced in the context of the "nonevents." Ideally, one should have all the gross information concerning the last 24 hours and subsequently analyze them. It is already a big step, thanks to the defibrillators the right to therapeutic error has been gained, a unique and fatal accident has been transformed into a repeatable event, and therefore, access is gained to the evolution of the responsible disease. I PACE 1995; 18[Pt. II].560–568)     

The Effects of Pneumothorax on Defibrillation Thresholds during Pectoral Implantation of an Active Can Implantable Cardioverter Defibrillator

Pneumothorax has previously been reported to increase defibriliation thresholds and lead impedance in monophasic systems. This article demonstrates a case using an active can system in which the lead impedance between the right ventricular defibriliation coil and the device improved from 70 il with pneumothorax to 48 Ω after resolution. The defibriliation threshold also improved from > 30 fto ≤ 10 J after the pneumothorax had resolved. We conclude that acute pneumothorax can increase the transthoracic lead impedance and defibriliation thresholds: however, with resolution both parameters can return to acceptable levels with an active can system.     

Multiple Inappropriate Shocks Precipitated by Interrogation of an Implantable Cardioverter Defibrillator

A 57-year-old man suffered multiple inappropriate shocks from an implantable cardioverter defibrillator that could not be inactivated because the magnet switch feature was deactivated. Attempts to interrogate the defibrillator caused shocks to be delivered. Emergent explantation was performed and a loose sensing lead was discovered. Sensing and defibrillation leads functioned normally, and testing of the explanted generator demonstrated no abnormalities. A new generator was put in place and the patient has been without shocks for 6 months. This case illustrates the need for robust methods of attenuating electromagnetic interference and the importance of multiple methods of device inactivation.     

Combination of Antitachycardia Pacemaker and Automatic Implantable Cardioverter/Defibrillator for Ventricular Tachycardia

Antitachycardia pacing for ventricular tachycardia (VT) is associated with the possibility of fibrillating the heart; on the other hand, the frequency of VT and patient discomfort can limit treatment with the automatic implantable cardioverter/defibrillator (AICD). To contribute to the further development of a universal pacemaker, we evaluated the combined use of the antitachycardia pacemaker ("tachylog") and the AICD in five patients with recurrent VT. In the automatic mode, the "tachylog" worked as a bipolar VVI pacemaker. For antitachycardia pacing, a burst of rapid ventricular pacing was delivered at about 80% of the cycle length. During a follow-up period of 5 +/- 2 months (range, 3 to 8) two to 291 successful interventions of antitachycardia pacing were counted from diagnostic data which had been collected by the pulse generator during the course of treatment. When the antitachycardia pacemaker failed to terminate VT, the AICD was activated. In the individual case, between 0 and 41 discharges of the AICD were delivered. The high pulse energy of the AICD did not damage the antitachycardia pacemaker; no interference of the two devices was observed. Future antitachycardia systems should be more flexible with regard to detection and termination modes, combining antitachycardia pacing with back-up defibrillation.     

Termination of Electrocution‐Induced Ventricular Fibrillation by an Implantable Cardioverter Defibrillator

We describe a case in which an implantable cardioverter defibrillator (ICD) saved a patient's life after he tried to commit suicide by electrocuting himself. Deaths caused by electrocution are usually accidental and rarely suicidal. The amount of current flow is the most important factor in deciding the degree of electrical injury, which may range from transient muscle tremors to death. The ICD is electrically insulated from surrounding electromagnetic interference and the passage of electric current typically does not damage or reprogram the device. In our patient, electromagnetic interference caused by the electric current initially triggered the noise reversion mode, leading to asynchronous pacing. Ventricular fibrillation was detected and terminated only after the electromagnetic interference stopped, as depicted by the intracardiac electrogram. This case is the first documented example of an ICD‐aborted fatal electrocution from ventricular fibrillation caused by an unnatural electrical source. (PACE 2010; 510–512)     

Tachycardia Sensing Failure of an Implantable Cardioverter Defibrillator in a Patient with Hypertrophic Cardiomyopathy

A 17-year-old white male was found to have nonobstructive hypertrophic cardiomyopathy after suffering three severe syncopal episodes. He experienced an episode of sustained polymorphic ventricular tachycardia during exercise tolerance testing that required cardioversion. Electrophysiological studies were able to reproduce sustained polymorphic ventricular tachycardia that was unresponsive to standard pharmacotherapy. An automatic implantable defibrillator was placed. However, during implantation with the rate sensing electrodes on the left ventricle, it was found that the extremely polymorphic nature of the tachycardia caused such rapid fluctuations in the sensed R wave signal that the device could not properly detect the tachycardia. This was felt to be due to the automatic gain control circuit of the Ventak 1550. The problem was solved by moving the rate sensing electrodes to the lateral right ventricle. This case suggests that the unique arrhythmic substrate of hypertrophic cardiomyopathy may present sensing difficulties during automatic implantable defibrillator insertion.     

Long-Term Follow-Up of Patients with Nonischemic Dilated Cardiomyopathy and Ventricular Tachyarrhythmias Treated with Implantable Cardioverter Defibrillators

We analyzed our 10-year cumulative experience of 40 consecutive patients with idiopathic dilated Cardiomyopathy and associated ventricular tachyarrhythmias, treated with implantable Cardioverter defibrillators. Dilated Cardiomyopathy was defined as left ventricular ejection fraction (EF) ≤50% with no defineable etiology. Patient characteristics included: 24 male, mean age 52 years, mean EF = 33%, New York Heart Association Class I–III, presenting syndrome—cardiac arrest (n = 28), syncope/near syncope (n = 12). At 2.5 years mean follow-up, there were 16 deaths: one operative, three sudden, two incessant ventricular tachycardia/ventricular fibrillation (VT/VF), six heart failure, and four noncardiac. The actuarial mortality at 1 and 4 years was 0% and 14% for sudden death, 11% and 34% for cardiac death. The projected mortality was 52% and 78% for same time intervals (P < 0.01). No useful baseline variable predicted who would or would not receive an ICD shock in follow-up. ICD therapy appears effective in reducing sudden death mortality in this high risk population.     

Combined Use of a True-Bipolar Sensing Implantable Cardioverter Defibrillator in a Patient Having a Prior Implantable Spinal Cord Stimulator for Intractable Pain

Reported is a case involving a patient with a previously implanted spinal cord stimulator (SCS) who presented for an implantable. Cardioverter defibrillator (ICD). The SCS device was located in the left lower abdominal quadrant with a stimulation electrode array placed on the dorsal aspect of the spinal cord at the T-11 thoracic level. Interaction testing demonstrated that the bipolar sensing transvenous ICD system (Medtronic 7221Cx PCD) did not detect the stimulator's output at burst rates ranging from 20–130 pulses/s, even with the ICD set to its maximum sensitivity of 0.15 mV and the stimulator programmed to the highest patient tolerated output combinations of 5 V, 0.45 ms in the bipolar configuration and 3 V, 0.45 ms in the unipolar (i.e., case-electrode) configuration.     

Failure of Third-Generation Implantable Cardioverter Defibrillators to Abort Shock Therapy for onsustained Ventricular Tachycardia Due to Shortcomings of the VF Confirmation Algorithm

Unnecessary shocks by ICDs for rhythms other than sustained VT or VF have been described as the most frequent adverse event in ICD patients. To avoid unnecessary shocks for self-terminating arrhythmias, the third-generation Jewel PCD defibrillators 7202, 7219, and 7220 Plus use a specially designed VF confirmation algorithm after charge end. The purpose of this study was to determine the ability of this VF confirmation algorithm to recognize nonsustained VT, and to analyze the reasons for failure of the PCD device to abort shock therapy for nonsustained VT despite use of this VF confirmation algorithm. Analysis of stored electrograms of electrical events triggering high voltage capacitor charging in the programmed VF zone of the device showed 36 spontaneous episodes of nonsustained VT (227 ± 21 beats/mm) during 18 ± 7 months follow-up in 15 patients who had a Jewel PCD implanted at our hospital. Intracardiac electrogram recordings and simultaneously retrieved marker channels demonstrated that the ICD shock was appropriately aborted according to the VF confirmation algorithm in 24 (67%) of 36 episodes of nonsustained VT. Twelve episodes (33%) of nonsustained VT, however, were followed by a spontaneous ICD shock in 6 (40%) of the 15 study patients. The only reason for all 12 shocks for nonsustained VT was the inability of the device to recognize the absence of VT after charge end due to shortcomings of the VF confirmation algorithm: 11 of the 12 shocks for nonsustained VT were triggered by the occurrence of paced beats during the VF confirmation period and 1 shock for nonsustained VT was triggered by the occurrence of 2 premature beats after charge end. Thus, better VF confirmation algorithms need to be incorporated in future PCD devices to avoid unnecessary shocks for nonsustained VT.     

Use of Atrial and Ventricular Electrograms from a Dual Chamber Implantable Cardioverter Defibrillator to Elucidate a Complex Dysrhythmia

Stored intracardiac electrograms provided by third-generation ICDs have proved their use in the analysis of the mechanism of tachydysrhythmic events. There are cases in which the analysis of ventricular electrograms is insufficient for the elucidation of certain dysrhythmias. The availability of atrial electrograms provided by dual chamber ICDs improves the diagnostic capability of electrogram analysis and could prove most useful especially in complex dysrhythmias.